Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Technetium-99m Market From 2025 to 2029?

In recent years, the market size for technetium-99m has experienced significant expansion, with projections indicating an increase from $4.52 billion in 2024 to $4.75 billion in 2025. This represents a compound annual growth rate (CAGR) of 5.1%. This growth throughout the historical period can be ascribed to various factors such as the broadening applications within nuclear medicine, enhanced demand for cancer and cardiac diagnostic procedures, an escalating dependence on molybdenum-99 supply, an increased demand for radiopharmaceuticals, and a growth in the utilization of imaging within clinical trials.

The market size for technetium-99m is set to witness consistent expansion over the next few years, reaching an estimated worth of $5.74 billion in 2029, reflecting a compound annual growth rate (CAGR) of 4.9%. This anticipated growth during the forecast period is resultant from enriched nuclear imaging potential, an escalating geriatric populace, an amplification in diagnostic volumes, an incrementing prevalence of cancer, and a rising adoption of hybrid imaging systems. Major future trends include the use of sustainable isotope technologies, the emergence of non-reactor-based production, progress in radiopharmaceutical technology, synergy with artificial intelligence, and innovation in the manufacturing of radiopharmaceuticals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25920&type=smp

What Elements Are Contributing To Growth In The Technetium-99m Market?

The escalating need for diagnostic imaging methods is anticipated to fuel the technetium-99m market’s expansion in the future. Diagnostic imaging methods are medical procedures that generate visual imagery of the body’s interior, aiding physicians in diagnosing and occasionally directing treatments for a variety of medical conditions. The surge in demand for such procedures stems from the growing rates of chronic diseases that necessitate prompt and precise diagnostics. Technetium-99m facilitates diagnostic imaging techniques by enabling doctors to scrutinize the functioning of organs and tissues with exceptional accuracy, leveraging its radioactive properties to generate comprehensive images in nuclear medicine scans. For example, the National Health Service (NHS) England, a governmental department based in the UK, reported that 45.0 million imaging tests were carried out in England from November 2023 to March 2023, a 2.2% rise from the 44.0 million tests conducted the prior year. Hence, the surging demand for diagnostic imaging methods is stimulating the growth of the technetium-99m market.

Which Segments Are Detailed In The Global Technetium-99m Market Report?

The technetium-99m market covered in this report is segmented –

1) By Product Type: Radiopharmaceuticals, Diagnostic Kits, Generators

2) By Formulation Type: Liquid, Solid, Freeze-Dried

3) By Application: Single Photon Emission Computed Tomography (SPECT) Imaging, Positron Emission Tomography (PET) Imaging, Oncology, Cardiology, Neurology, Other Applications

4) By End-User: Hospitals, Diagnostic Imaging Centers, Research Laboratories, Specialized Clinics, Other End-Users

Subsegments:

1) By Radiopharmaceuticals: Sestamibi, Tetrofosmin, Sulfur Colloid, MAA (Macroaggregated Albumin), DTPA (Diethylenetriaminepentaacetic Acid), Others

2) By Diagnostic Kits: Cardiac Imaging Kits, Bone Imaging Kits, Renal Imaging Kits, Hepatobiliary Imaging Kits, Pulmonary Imaging Kits, Others

3) By Generators: Hospital-Based Generators, Centralized Radiopharmacy Generators

What Long-Term Trends Are Likely To Affect The Technetium-99m Market?

Leading businesses involved in the technetium-99m industry are prioritizing the creation of inventive solutions such as advanced radiopharmaceutical imaging agents. These solutions aim to augment precision and availability of diagnostic imaging procedures for intricate health conditions. These advanced radiopharmaceutical imaging agents are particular compounds marked with radioactive elements that give visibility to doctors into the human body through imaging modalities. For example, Serac Healthcare Limited, a clinical radiopharmaceutical organization domiciled in the UK, was granted Fast Track Designation by the US Food and Drug Administration (FDA) in June 2024 for 99mTc-maraciclatide. This is a unique single-photon emission computed tomography (SPECT)-computed tomography (CT) imaging compound for visualizing and diagnosing superficial peritoneal endometriosis. It’s applicable for females who are 16 years or older. The 99mTc-maraciclatide, being a technetium-99m-labeled targeted peptide imaging compound, connects with integrins found in abundance in endometriosis lesions, making it possible to see disease sites during SPECT-CT scans clearly. This constitutes a non-invasive diagnostic alternative to laparoscopic procedures, offering females suspected of endometriosis a more secure and easily accesible diagnostic route. The compound utilizes the superior imaging attributes of technetium-99m, namely its optimal half-life and gamma emission energy, in order to yield high-definition diagnostic images while lowering patient radiation exposure. This development is set to boost diagnostic precision and simplify treatment choices in endometriosis management, whilst broadening the clinical usages of technetium-99m-based imaging in the realm of women’s health.

Who Are The Key Contributors To Growth In The Technetium-99m Market?

Major companies operating in the technetium-99m market are Cardinal Health Inc., Siemens Healthineers AG, Philips Healthcare, GE Healthcare Technologies Inc., BWX Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., China Isotope & Radiation Corporation (CIRC), Jubilant Pharma Limited, Curium Pharma LLC, Eckert & Ziegler Strahlen, Telix Pharmaceuticals Limited, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd., Advanced Cyclotron Systems Inc., Cyclopharm Limited, SHINE Technologies LLC, Medi-Radiopharma Kft., SDS Lifesciences Pvt Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/technetium-99m-global-market-report

Which Region Is Projected To Lead The Technetium-99m Market By 2025?

North America was the largest region in the technetium-99m market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the technetium-99m market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25920&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model